# **Product** Data Sheet

# FT895

Cat. No.: HY-112285 CAS No.: 2225728-57-2 Molecular Formula:  $C_{16}H_{15}F_3N_4O_2$ Molecular Weight: 352.31

Target: HDAC

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage: Powder -20°C

3 years 4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 125 mg/mL (354.80 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8384 mL	14.1920 mL	28.3841 mL
	5 mM	0.5677 mL	2.8384 mL	5.6768 mL
	10 mM	0.2838 mL	1.4192 mL	2.8384 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	FT895 is a potent and selective HDAC11 inhibitor with an IC $_{50}$ of 3 nM $^{[1]}$ .	
IC <sub>50</sub> & Target	HDAC11 3 nM (IC <sub>50</sub> )	
In Vitro	FT895 is a highly selective HDAC11 inhibitor showing greater than 1000-fold selectivity against the other 10 members of the HDAC family $^{[1]}$ .	



## **CUSTOMER VALIDATION**

• Redox Biol. 3 September 2022, 102461.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Martin MW, et al. Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorg Med Chem Lett. 2018 Jul 1;28(12):2143-2147.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com\\$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA